Cyclooxygenase products and atherosclerosis

about

Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life Role of endothelium-dependent hyperpolarisation and prostacyclin in diabetes.Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis.

P2860

Q33735189-BECF4C34-4B0E-4B9D-B695-E241323B9163 Q35625597-16C08900-2CD4-42BC-9BD3-24049D8CB66B Q37039326-0EA5A3DD-8E75-47CF-9B75-580F7D7AEE96

P2860

Cyclooxygenase products and atherosclerosis

Item

http://www.wikidata.org/entity/Q37071164

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cyclooxygenase products and atherosclerosis

@en

Cyclooxygenase products and atherosclerosis.

@nl

type

Item

label

Cyclooxygenase products and atherosclerosis

@en

Cyclooxygenase products and atherosclerosis.

@nl

prefLabel

Cyclooxygenase products and atherosclerosis

@en

Cyclooxygenase products and atherosclerosis.

@nl

P1476

Cyclooxygenase products and atherosclerosis

@en

P2093

Macrae F Linton

http://www.w3.org/2001/XMLSchema#string

Sergio Fazio

http://www.w3.org/2001/XMLSchema#string

P2860

A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling

Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2

The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1

Cyclooxygenase in biology and disease.

Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease

Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes

Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups

Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

Role of prostacyclin in the cardiovascular response to thromboxane A2

P304

25-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DDSTR.2008.05.006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24254598

http://www.w3.org/2001/XMLSchema#string

P698

19343100

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

2630286

http://www.w3.org/2001/XMLSchema#string

Cyclooxygenase products and atherosclerosis

about

P2860

P2860

Cyclooxygenase products and atherosclerosis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932